Kornimate/medical-research-clean huggingface dataset:
mr-us image fusion targeted biopsy for single-cell prostate cancer research

Conditions: Prostate Cancer

Summary: the investigators hypothesize that this single-cell analysis can be used to evaluate prostate needle-core biopsies prospectively even in non-homogenous samples by providing profiles of proteomic and phenotypic signatures. these profiles will in turn enable better predictions of the malignant progression of prostate cancers in the settings of current clinical practice.

current approaches for early detection and diagnosis include prostate-specific antigen (psa) which is a useful, though not specific, biomarker for detecting prostate cancer. the suspected patients will be further sent for digital rectal examination(dre), in which a doctor inserts a lubricated, gloved finger into the patient's rectum to feel for lumps, enlargements, or areas of hardness that might indicate prostate cancer. however, the only test that can fully confirm the diagnosis of prostate cancer is a biopsy - the removal of small pieces of the prostate for microscopic examination. if cancer is suspected using psa test and dre, more than 90% suspected patients choose undergo prostate biopsy. prostate needle biopsies are routinely done on an outpatient basis and rarely require hospitalization. markedly, the fine needle biopsy is minimally invasive and has currently been suggested for longitudinal monitoring of highly suspected patients or follow-up therapeutic responses. the large availability of biopsy samples for prostate cancer provides a cornerstone for the proposed patient specimen-based research. the investigators anticipate that comprehensive analysis rather than simple pathological examination of these samples will generate new insights to prostate tumor progression in human.

Eligibility criteria:
inclusion criteria: * only subjects that have scheduled artemis prostate biopsy with defined regions of interest will be included in this study exclusion criteria: * any subjects that are unable to provide informed consent will be excluded
alveolar bone loss around 3 different designs of dental implant: prospective comparative clinical trail

Conditions: Alveolar Bone Loss

Summary: comparison of alveolar bone resorbtion/ changes for a period of 12 month post loading of different designs and brands of oral implants. in this study, a comparison between straumann sla-active implants to mis mistral and mistral -x implants.


Eligibility criteria:
inclusion criteria: * healthy * \>18y * consent * posterior mandibular missing teeth exclusion criteria: * chronic illness: diabetes, artheritis * women: pregnancy, lactation * non consent * alcohol consumption * smoking \>10 p day

Keywords: alveolar bone radiographic alveolar bone changes around oral implants of various designs 12 m post loading
study of temozolomide in previously untreated acute myeloid leukemia (aml) and myelodysplastic syndrome (mds) participants with low o6-methylguanine methyltransferase (mgmt) expression (p05052)

Conditions: Leukemia, Acute Myeloid; Myelodysplastic Syndrome

Summary: the primary objective of this study is to evaluate the safety, tolerability, and efficacy of temozolomide in acute myeloid leukemia (aml) and myelodysplastic syndrome (mds) participants who are not candidates for standard induction therapy and exhibit low mgmt expression.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of acute myeloid leukemia (aml), any subtype except acute promyelocytic leukemia (apl), by the world health organization (who) criteria, or high risk mds with blasts between 10 and 20% in the bone marrow. * no prior aml chemotherapy except hydroxyurea. * leukemic blast count \<30x10\^9/l at the start of therapy. prior cytoreduction with hydroxyurea (maximum 14 days) is permitted. * participant is not a candidate for aggressive induction based on at least one of the following: adverse-risk cytogenetics (complete or partial deletion of 5 or 7, complex \[\>3\] cytogenetic abnormalities, inv3, 11q23 abnormalities); secondary aml (antecedent hematologic disorder or therapy-related aml); comorbid medical illnesses precluding standard induction therapy; participant's refusal of standard induction therapy. * confirmed low mgmt expression (mgmt: beta-actin ≤0.2), as evaluated by western blot, or weak mgmt expression defined as \> 0.2 and ≤2.5 if promoter is methylated, upon sponsor approval. * eastern cooperative oncology group (ecog) performance status of 0, 1, or 2. * use of medically approved contraception in fertile males and females. * negative urine or serum pregnancy test for women of childbearing potential (72 hours prior to baseline). exclusion criteria: * serum bilirubin \>2 times the upper limit of normal (uln), or serum aspartate aminotransferase/ alanine aminotransferase \>5 times uln. * serum creatinine \>200 umol/l. * history of other malignancies within 1 year prior to study entry, with the exception of localized nonmelanomatous skin cancer or cervical cancer in situ. * presence of active uncontrolled infection. * known human immunodeficiency virus (hiv) infection. * any medical condition that may interfere with protocol evaluation or oral medication intake. * prior chemotherapy other than hydroxyurea.
media and social networks consultation and associated factors among orthodontic patients

Conditions: Dental Care; Using Social Media and Networks to Find Out About Orthodontic Treatment

Summary: "context : an increasing number of patients are using the internet and social media to obtain information about oral health, including the field of orthodontics. aim : this study aimed to analyze the behavior and habits of patients regarding the use of social media to obtain information about orthodontics, as well as the factors associated with this usage. materials and methods : the study was designed as a single-center, cross-sectional, descriptive study. orthodontic patients filled out a 28-question questionnaire that gathered demographic data, information-seeking behavior, platform use and online consultation habits, trust and impact, and interest in additional resources. a univariate and multivariate logistic regression models/analysis were conducted using excel and ibm spss statistics version 29.0.1.0, (employing chi2, fisher's exact tests, univariate and multivariate models)."


Eligibility criteria:
inclusion criteria: - all patients, whether adults or minors accompanied by their legal representative, who consulted in the orthodontics unit, and had access to the internet. exclusion criteria: - all patients who declined to participate.
comparison of insulin pump and mdi for pregestational diabetes during pregnancy

Conditions: Type 1 Diabetes; Type 2 Diabetes; Pregnancy

Summary: this study is investigating whether insulin treatment with the insulin pump or with multiple daily injections (mdi) gives better outcomes for mother and baby in pregnant women with pregestational diabetes. participants will be randomized to use either the insulin pump or mdi.

primary outcome is a composite of cesarian section, instrumental delivery, maternal hypertension, lga infant, neonatal hypoglycemia or scn admission.

Eligibility criteria:
inclusion criteria: * subjects are attending the diabetes pregnancy clinic at participating hospitals * have had type 1 or type 2 diabetes for at least one year * are in the first trimester or are actively attempting pregnancy * have a singleton pregnancy * are receiving intensive insulin therapy * are judged by clinic staff to be capable of using an insulin pump * are age 19 or older * are willing to adhere to the study protocol including monitoring blood glucose levels * are willing to take folic acid before pregnancy and during the first trimester * are willing to discontinue any medication contraindicated in pregnancy prior to conception * weigh less than 100 kg (220 lb) prior to becoming pregnant * use less than 100 units of insulin per day exclusion criteria: * current or previous use of an insulin pump * use of fertility treatments * have a multiple pregnancy * have had children born with major birth defects * have experienced stillbirth or multiple early pregnancy losses * have significant diabetes complications or a serious medical issue

Keywords: insulin pump csii multiple daily injections mdi type 1 diabetes type 2 diabetes pregnancy
outcome of cerebral venous sinuses stenting on idiopathic intracranial hypertension

Conditions: Idiopathic Intracranial Hypertension

Summary: the aim of the work is to asses the positive effect of stenotic sinus segment stenting on idiopathic intracranial hypertension with headache and papilloedema.

participants the study will include group of patients with an established diagnosis of idiopathic intracranial hypertenton meeting our inclusion criteria and will admitted to al-azher univerity hospitals (al-hussien and bab el-shaeria) after informed consent from them. the recruitment will take place after approval from the ethics committee and the university council. * they are selected according to the modified dandy criteria to diagnose iih: 1. grade ii paplledema . 2. normal neurological examination except for six nerve palsy. 3. neuroimaging criteria of normal brain parenchyma without evidence of hydrocephalus, mass or structural lesion and no abnormal meningeal enhancement on mri. 4. normal csf composition. 5. elevated lumbar puncture opening pressure, defined as greater than or equal to 250 mmh2o in adults (7). * exclusion criteria included: 1. age less than orequal to 18 years. 2. creatinine .1.5 mg/dl. 3. severe allergic reaction to iodine contrast. 4. contraindication to general anesthesia, use of aspirin, clopidogrel or anticoagulants, thrombophilic disorder or anticardiolipin syndrome. 5. dural arteriovenous fistula or other arteriovenous lesion affecting cortical venous flow. 6. pregnancy. 7. blood pressure must be measured to exclude malignant hypertension, as defined as a diastolic blood pressure greater than or equal to 120 mm hg or systolic blood pressure greater than or equal to 180 mm hg(17).

Eligibility criteria:
inclusion criteria: * 1. grade ii paplledema . 2. normal neurological examination except for six nerve palsy. 3. neuroimaging criteria of normal brain parenchyma without evidence of hydrocephalus, mass or structural lesion and no abnormal meningeal enhancement on mri. 4. normal csf composition. 5. elevated lumbar puncture opening pressure, defined as greater than or equal to 250 mmh2o in adults exclusion criteria: * 1. age less than to 18 years. 2. creatinine .1.5 mg/dl. 3. severe allergic reaction to iodine contrast. 4.contraindication to general anesthesia, use of aspirin, clopidogrel or anticoagulants, thrombophilic disorder or anticardiolipin syndrome. 5. dural arteriovenous fistula or other arteriovenous lesion affecting cortical venous flow. 6. pregnancy.

Keywords: idiopathic intracranial hypertension stenting
xp13512 (gsk1838262) versus placebo in patients with restless legs syndrome.

Conditions: Restless Legs Syndrome

Summary: the primary objective of this trial is to assess the efficacy of xp13512 taken once daily compared to placebo for the treatment of patients suffering from restless legs syndrome (rls).


Eligibility criteria:
inclusion criteria: * patients with primary rls, based on the international rls study group diagnostic criteria. * history of rls symptoms at least 15 nights in the prior month or, if on treatment, this frequency of symptoms before treatment was started; * documented rls symptoms for at least 4 of the 7 consecutive evenings/nights during the baseline study period; * total rls severity score of 15 or greater on the international restless legs syndrome study group rating scale (irls rating scale) at visit 1 and at visit 2; * discontinuation of dopamine agonists and/or gabapentin at least 2 weeks prior to baseline; * discontinuation of other treatments for rls (e.g., opioids, benzodiazepines) at least 2 weeks prior to baseline; * if female of child-bearing potential, the subject must agree to use clinically accepted birth control through completion of the study; * body mass index of 34 or below; * estimated creatinine clearance of at least 60 ml/min; exclusion criteria: * a sleep disorder (e.g., sleep apnea) that may significantly affect the assessment of rls; * neurologic disease or movement disorder (e.g., diabetic neuropathy, parkinson's disease, multiple sclerosis, dyskinesias, and dystonias); * abnormal laboratory results, electrocardiogram (ecg) or physical findings; * pregnant or lactating women; * women of childbearing potential who are not practicing an acceptable method of birth control.
racial differences in vagal control of glucose homeostasis, chronic study

Conditions: Insulin Sensitivity; Oxidative Stress

Summary: investigators will test the hypothesis that chronic restoration of vagal nerve activity with a central acetylcholinesterase inhibitor improves insulin sensitivity and reduces adipose tissue oxidation in obese african american women compared to white women.

investigators will test the hypothesis that chronic restoration of parasympathetic nervous system (pns) activity with a central acetylcholinesterase inhibitor improves insulin sensitivity and reduces adipose tissue oxidation in obese african american women (aaw) compared to white women (ww). a cross-over study will be performed in matched cohorts of aaw and white women subjected to chronic central acetylcholinesterase inhibition with galantamine versus placebo, given orally over a 4-week period. insulin sensitivity will be measured using the gold standard hyperinsulinemic-euglycemic clamp. adipose tissue will be obtained through subcutaneous fat biopsies where f2-isoprostanes will be quantified.

Eligibility criteria:
inclusion criteria * female * african american or white (race will be self-defined, but only subjects who report both parents of the same race will be included) * 18-60 years old * bmi 30-45 kg/m2 * not pregnant or breastfeeding exclusion criteria * pregnant or breastfeeding * diabetes diagnosis (defined by the american diabetes association (ada) criteria)38 * cardiovascular disease such as myocardial infarction within 6 months prior to enrollment, presence of angina pectoris, significant arrhythmia, congestive heart failure (lv hypertrophy acceptable), deep vein thrombosis, pulmonary embolism, mitral valve stenosis, aortic stenosis, or hypertrophic cardiomyopathy. * arrhythmia (first-, second-, and third-degree av block) * significant weight change \>5% in the past 3 months * impaired hepatic function (ast and/or alt \>1.5x upper limit of normal range) * impaired renal function (egfr \<60ml/min) * users of strong inhibitors of cyp3a4 or cyp2d6 * users of other acetylcholinesterase inhibitors such as pyridostigmine or bethanechol * history of alcohol or drug abuse * mental conditions rendering the subject unable to understand the nature, scope, and possible consequences of the study * inability to comply with the protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study * steroid use within 6 weeks prior to study entry * any underlying or acute disease requiring regular medication which could possibly pose a threat to the subject or make implementation of the protocol or interpretation of the study results difficult * discretion of the investigator

Keywords: insulin sensitivity african american obese
anterior cruciate ligament reconstruction with a periosteal - patellar tendon - bone autograft - the kocabey press-fit technique

Conditions: Anterior Cruciate Ligament Rupture

Summary: this study aims to evaluate the clinical and radiological outcomes of patients undergoing anatomical single-bundle anterior cruciate ligament reconstruction with periosteal-patellar tendon-bone autograft and press-fit tibial fixation technique. the study also aims to compare these outcomes with other reconstruction techniques in the literature. the research investigates the results of a novel surgical technique, providing a minimally invasive and faster rehabilitation for patients undergoing surgery due to anterior cruciate ligament rupture. the technique does not use any screws or staples for tibial fixation, but it carries similar risks as existing techniques. the technique, similar to the well-known bone-patellar tendon-bone (bptb) autograft technique, creates minimal bone defect at the tibial tuberosity. over time, the defect remodels and causes minimal clinical discomfort. despite these limitations, the authors expect patients operated with the investigated new technique to experience less postoperative swelling, less pain, faster mobilization, and earlier rehabilitation.


Eligibility criteria:
inclusion criteria: * patients who underwent anatomical single-bundle anterior cruciate ligament reconstruction with periosteal - patellar tendon - bone autograft and press-fit tibial fixation technique after anterior cruciate ligament rupture * patients with at least 1 year of clinical and radiological follow-up * patients who did not undergo a revision exclusion criteria: * patients who underwent a secondary arthroscopy for any reason after primary surgery * patients with a history of septic arthritis (before and after the surgery) * those with a history of trauma after primary surgery to the operated knee * patients who have not completed at least 1 year of follow-up

Keywords: anterior cruciate ligament rupture press-fit fixation patellar tendon graft
post-covid-19 chronic fatigue syndrome

Conditions: Post-COVID-19 Syndrome; Post-COVID Syndrome

Summary: fatigue is recognized as one of the most commonly presented long-term complaints in individuals previously infected with sars-cov-2.

it has become increasingly clear that infected patients have symptoms not only in the acute phase, but also after recovery from the initial infection. a recent meta-analysis including 4828 patients with post-covid-19 showed that symptoms and post-acute sequelae of sars-cov-2 can persist weeks to months after the infection. these patients who reported persistent symptoms have been termed "long haulers" or described as having long covid, post-acute covid-19, persistent covid-19 symptoms, post covid-19 manifestations, long-term covid-19 effects, post-acute sequelae of covid-19 (pasc), or post-covid-19 syndrome.

Eligibility criteria:
inclusion criteria: * age . 18 * male or female * post-covid-19 fatigue exclusion criteria: * refusal
the efficacy of interferential current treatment on knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: the effects of different carrier frequencies of interferential current on pain and function in patients with knee arthrosis will be compared

60 patients with knee osteoarhthritis will be enrolled in the study. subjects will be randomized to 3 groups. all patients will receive interferential currents to both their knees, with different carrier frequencies (2, 4 and 8 kilohertz (khz) respectively). the effect of different types of carrier frequencies on pain, 10 meter walk test will be analysed.

Eligibility criteria:
inclusion criteria: * age between 50-80 years * knee vas pain scores ≥ 4 * kellgren-lawrence radiologic scores 2 and 3 exclusion criteria: * history of knee surgery * inflammatory arthritis * paralysis of lower extremities * serious cardiovascular disease /presence of cardiac pacemaker * severe osteoarhthritis of lower extremity joints other than the knees * history of newly diagnosed cancer (ın the last 6 months) * cognitive impairment

Keywords: interferential current knee osteoarthritis pain
prospective, multi-center all-comer biliary canadian wallflex registry

Conditions: Biliary Strictures

Summary: the purpose of this study is to document stent functionality and practice patterns in canada pertaining to indications for use and stent type selection for self-expanding biliary metal stents (sems) when used per standard of practice.

this study is designed to provide a report of these features related to the use of wallflex metal biliary stents used per standard of practice in canada.

Eligibility criteria:
inclusion criteria: * subject indicated for biliary metal stent placement per local standard of practice * age 18 or older * willing and able to comply with study procedures and follow-up schedule * willing and able to provide written informed consent to participate in study exclusion criteria: * subjects who are currently enrolled in another investigational study that would directly interfere with the current study, without prior written approval from the sponsor * subjects who the investigator deems at risk for device or procedure related complications per the directions for use (dfu)
the development of a system for measurement of tremor

Conditions: Essential Tremor; Dystonia

Summary: the goal of this clinical trial is to develop a system which can be used to measure movements in people with essential tremor (with or without dystonia). the main questions it aims to answer are: * can individuals with essential tremor be distinguished from individuals without tremor using virtual reality (vr) * can the current essential tremor assessment scale (the tetras) be reproduced in vr * can essential tremor be quantified using a measurement system * can dystonia be quantified using a measurement system. participants will don the equipment used to measure their tremor and replicate a series of standardized movements to measure their tremor, in and out of the vr platform. the assessment will take no longer than an hour.

this study aims to develop a way of objectively measuring the neurological disorders, essential tremor (et) and dystonia. these conditions can affect the upper and lower limbs, head, voice, face and trunk. et and dystonia can be difficult to assess and treat, particularly if severe, and therapies are limited. currently the severity of these conditions is formally assessed by clinician rated scales such as the essential tremor rating assessment scale (tetras) which is biased towards the upper limbs, requires training and is not objective. there is a need for a more precise, less variable measure of tremor that can used easily be non-expert clinicians. this study questions whether it is possible to quantify et and dystonia using a measurement system in a virtual reality (vr) environment. data will be collected from measurement sensors embedded in the vr environment from healthy control participants, and those with et with and without dystonia. participants will be placed in a vr environment and instructed to perform the tetras. this will help to develop an algorithm which can measure et severity using machine learning. it is expected that the algorithm will provide a better assessment of et and dystonia than the tetras. this study may pave the way towards the development of simpler devices to which the algorithm can be applied.

Eligibility criteria:
inclusion criteria - control participants * aged 18 to 80 years * able to provide informed consent for self * able to comply with all study procedures exclusion criteria -control participants * any neurological disorder * any other non-neurological cause of tremor e.g. medication induced inclusion criteria - et participants * aged 18 to 80 years * able to provide informed consent for self * clinical diagnosis of et or et plus syndrome * able to comply with all study procedures exclusion criteria - et participants * tremor other than et (e.g. parkinsonian, functional tremor) * presence of other movement disorder * for deep brain stimulation (dbs) participants: unwilling or unable to turn off and on their own stimulator for the duration of the study.

Keywords: essential tremor dystonia virtual reality biokin